ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call.
Zynex management will host the conference call.
Date: Tuesday, November 18, 2025
Time: 9:00 AM Eastern Time (7:00 PM Mountain Time)
U.S. & Canada dial-in number: 800-836-8184
International number: 646-357-8785
Webcast: Q3 2025 Webcast Link
The Company will also provide a link at https://zynexmed.investorroom.com/ for those who wish to stream the call via webcast. Please call the conference telephone number 5-10 minutes prior to the start time.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Vikram Bajaj, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.57 |
| Daily Change: | -0.20 -26.28 |
| Daily Volume: | 2,710,802 |
| Market Cap: | US$17.390M |
November 14, 2025 October 14, 2025 August 18, 2025 July 31, 2025 June 30, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
